Cell Therapeutics, Inc. (CTIC)
The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.
Recs
The new drug is about to go into phase 3 and the stock will explode!
Recs
cancer drugs in the pipeline with possible good outcomes.....
Recs
Good entry point for mid to long term.
I couldn't get in until it got above a dollar to rate it although been watching since .o7/shr.
Probably could of got in lower, but lost track watching others.
Recs
CTIC has just asked the FDA to approve pixantrone for refractory aggressive non-Hodgkin's lymphoma, a form of cancer. It's still very early in the process but a good long-term bet that if the drug is approved, this will give this stock a significant boost.
Recs
New cancer drug looks like it will be accepted by FDA.
Recs
A pipeline of drugs in advanced trials with promising efficacy results, paring of debt, a recent $30 million infusion of cash - and they've been around since 1991.
I figure they ain't going to -0-.
Recs
Best Bio Bets
Recs
Bit risky but should double within a few months and i would cash out if it doubles
Recs
I HAVE BEEN FOLLOWING CTIC FOR ABOUT 6 MONTHS NOW...HAVE CASHED OUT ON PROFITS ONCE SO FAR AND WILL AGAIN VERY SOON. TOOK PART IN THE PHONE UPDATE THIS MORNING AND BOUGHT ANOTHER BLOCK OF STOCKS...I'M A STRONG BELIEVER THAT THIS STOCK WILL SOON TAKE OFF.
FDA WILL DECIDE ABOUT FAST TRACK LATER THIS MONTH...SHOULD SEE A JUMP IN STOCK STRENGTH IN THE WEEK LEADING UP TO THE ANNOUNCEMENT THEN ANOTHER JUMP IF CTIC RECEIVES A FAVORABLE DECISSION. DECEMBER 24TH WILL THEN BRING A VERY HAPPY HOLIDAY TO THE SHAREHOLDERS. LET IT BE WRITTEN ...LET IT BE DONE!
Recs
Pussing several promissing drugs to market, plenty of cash on hand, look at the price, cant go anywhere but up......
Recs
The National Cancer Institute presented on July 20 a new preclinical research identifying unique anti-tumor mechanisms of brostallicin that sets this agent apart from other currently used chemotherapy agents. CTI acquired worldwide rights to brostallicin when it acquired privately-held Systems Medicine LLC in 2007. This stock should be going up at no time.
read to full report:
http://finance.yahoo.com/news/National-Cancer-Institute-prnews-2409163949.html?x=0&.v=1
Recs
3 major new cancer fighting drugs just had successful trials and should roll out over the next few months, conservatively doubling the stock price by year's end.
Recs
Drugs in pipeline.
Recs
Then next Dendreon.
Recs
Their products are unique and effective within the biotech industry.
Recs
I believe that Cell Therapeutic's new drug, Pixantrone will help this company go over the top. They've recently submitted it to the FDA and if it goes thru, the stock prices could really climb.
Recs
this thing is run by one of the most overpaid CEOs that has used this company as his own personal piggy bank
near half a million in salary and bonuses during a year the pps was down over 90% ?!? Ha
however, the drug, and what it can do for many people makes me sad indeed of the mgmt team
Recs
cti has 2 phase IIII cancer treatment drugs pixantrone & opaxio and another drug in phase III brostallicin. I think this stock will skyrocket very soon.
Recs
Speculative bet on a decent biotech with a good caps score and high user ratings.
Recs
New drug to hit the market soon.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 51 1 2 3 Next »